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We report a sensitive, magnetic bead-based colorimetric assay for Plasmodium falciparum lactate de-
hydrogenase (PfLDH) in which the biomarker is extracted from parasitized whole blood and puriﬁed
based on antigen binding to antibody-functionalized magnetic particles. Antigen-bound particles are
washed, and PfLDH activity is measured on-bead using an optimized colorimetric enzyme reaction (limit
of detection [LOD] ¼ 21.1 ± 0.4 parasites/ml). Enhanced analytical sensitivity is achieved by removal of
PfLDH from the sample matrix before detection and elimination of nonspeciﬁc reductases and species
that interfere with the optimal detection wavelength for measuring assay development. The optimized
assay represents a simple and effective diagnostic strategy for P. falciparummalaria with time-to-result of
45 min and detection limits similar to those of commercial enzyme-linked immunosorbent assay (ELISA)
kits, which can take 4e6 h. This method could be expanded to detect all species of malaria by switching
the capture antibody on the magnetic particles to a pan-speciﬁc Plasmodium LDH antibody.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Malaria is a treatable infectious disease responsible for nearly
600,000 deaths annually worldwide [1]. The disease, caused by
Plasmodium spp., is transmitted when a mosquito injects sporozo-
ites, which infect the liver in a human host. From the liver, the
parasite infects circulating red blood cells and enters an asexual
intraerythrocytic cycle. In this cycle, the malaria infection can
become symptomatic and detectable.
Plasmodium parasites rely on anaerobic metabolism to generate
energy during the asexual intraerythrocytic cycle. Plasmodium
lactate dehydrogenase (pLDH) is the terminal enzyme in the
glycolytic pathway, converting pyruvate to lactate using cofactor
NADH [2]. Slight structural changes in the active site of pLDH result
in substrate and cofactor speciﬁcity distinguishable from hosthydrogenase; hLDH, human
ine dinucleotide; NBT, nitro-
II, histidine-rich protein II;
, recombinant P. falciparum
DH; PBS, phosphate-buffered
eionized; TBST, Tris-buffered
tion; ELISA, enzyme-linked
is), david.wright@vanderbilt.edu
Inc. This is an open access article uhuman lactate dehydrogenase (hLDH) [3]. Speciﬁcally, the
replacement of Ser163 in hLDH with Leu163 in pLDH confers ac-
tivity with 3-acetylpyridine adenine dinucleotide (APADþ), an
analog of NADþ [3]. The parasite enzyme is 300 times more active
with APADþ than is hLDH [4]. Taking advantage of this kinetic dif-
ference, Makler and Hinrichs developed the Malstat assay for the
speciﬁc detection of pLDH [5]. In this assay (Scheme 1), pLDH in an
infected lysed blood sample oxidizes lactate to pyruvate while
reducing cofactor APADþ to APADH. The APADH then reduces a
yellow tetrazolium dye, nitroblue tetrazolium (NBT), to a blue
diformazan compound with the assistance of phenazine etho-
sulfate (PES). Reaction progress is followed at 650 nm. This assay is
frequently used to assess parasite viability in drug susceptibility
assays because pLDH activity has been shown to follow closely with
parasitemia [6].
In addition to amarker of parasite viability, pLDH is an appealing
diagnostic biomarker for malaria for several reasons. First, pLDH is
conserved across all four Plasmodium species known to infect
humans, whereas histidine-rich protein II (HRPII), a common ma-
larial biomarker, is speciﬁc only for Plasmodium falciparum [7].
Second, pLDH activity in host circulation clears within 24 h after
successful treatment, leading to fewer false-positive diagnoses due
to biomarker persistence after elimination of infection, a common
occurrence with HRPII [8]. Third, due to fast clearance, detection of
pLDH could be used for malaria case management.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Scheme 1. Malstat assay for the detection of Plasmodium lactate dehydrogenase.
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a diagnostic tool due to the short assay time; however, studies have
shown that samples with low parasite densities cannot be
measured due to nonspeciﬁc reductases in blood [9]. To address
this, Piper and coworkers developed an immunocapture Malstat
assay in which immobilized monoclonal anti-pLDH antibodies in
the wells of a 96-well plate captured P. falciparum lactate dehy-
drogenase (PfLDH) from lysed parasite blood. The wells were
washed and incubated with Malstat reagents, and the resulting
signal was measured at 650 nm. Although this process eliminated
nonspeciﬁc reductases from blood, the assay proved to have a
sensitivity of only 62% for samples with parasite densities between
50 and 500 parasites per microliter, likely due to unoptimized
signal detection conditions [10].
This work aimed to increase the analytical sensitivity and
decrease the detection limit of the Malstat assay into diagnostically
relevant parasitemias using antibody-functionalized magnetic mi-
croparticles to separate and purify PfLDH from parasitized lysed
whole blood. Immunomagnetic biomarker capture is advantageous
because nonspeciﬁc reductases and other interfering species are
eliminated from the detection step. Furthermore, high surface area
for antigen binding and active mixing allow for increased analytical
sensitivity and decreased time-to-result, respectively, compared
with 96-well plate-based immunoassays.
Materials and methods
Reagents and materials
Sodium L-lactate, 3-acetylpyridine adenine dinucleotide, and
phenazine ethosulfate were purchased from SigmaeAldrich (cat.
nos. L7022, A5251, and P4544, respectively). Nitroblue tetrazolium
chloride was purchased from Life Technologies (cat. no. N-6495).
Recombinant P. falciparum lactate dehydrogenase (rcPfLDH) was
purchased from CTK Biotech (cat. no. A3005). P. falciparumD6 strain
was cultured in the lab. Anti-P. falciparum LDH antibodies were
purchased from MyBioSource (cat. no. MBS832018). Dynabeads
MyOne Streptavidin T1were purchased from Life Technologies (cat.
no. 65601).
Magnetic bead preparation
Anti-P. falciparum LDH (a-PfLDH) antibodies were biotinylated
with EZ-Link NHSePEG4eBiotin, No-Weigh Format (Thermo
Pierce, cat no. 21329), in phosphate-buffered saline (PBS) with a
50  excess of NHSePEG4eBiotin. Excess NHSePEG4eBiotin was
removed using Zebra Spin Desalting Columns with a 7000-Da
molecular weight cutoff (Thermo Pierce, cat. no.89882). Next,
3 mg of Dynabeads MyOne Streptavidin T1 were washed three
times with PBS containing 0.01% Tween 20 (PBST) before 30 min ofincubationwith 600 ml of 0.33 mg/ml biotinylated a-PfLDH antibody
in PBS. The beads were then washed three times with PBST and
blocked with excess D-biotin in PBS for 30 min. Finally, the beads
were washed three times and resuspended in 300 ml of PBST.
PfLDH activity assay optimization
Optimizing the PfLDH activity assay involved maximizing reac-
tion rates and minimizing background signal. In the ﬁrst kinetics
experiment [APAD] was held constant and [L-lactate] was varied. A
2.86-M solution of sodium L-lactate 0.22 M Tris buffer (pH 9.0, TB)
was prepared (3.2 g in 10 ml) and serially diluted by a factor of 2.
Next, 62.5 ml of each sodium L-lactate dilution, 62.5 ml of 1.33 mM
APAD in TB, and 50 ml of 7 nM rcPfLDH in TB were placed in wells in
triplicate of a Costar UV-transparent 96-well plate (cat. no. 3635)
such that the ﬁnal well concentrations were 0.474 mM APAD; 2 nM
rcPfLDH; and 0.00, 15.9, 31.9, 63.8, 128, 255, 510, and 1020 mM
sodium L-lactate. The plate was immediately placed in a BioTek
Synergy H4 Hybrid Multi-Mode Microplate Reader, and APADH
generation was measured by absorbance (362 nm,
ε¼ 9.1 103 M1 cm1) [11] in intervals of 25 s for 30 min. The rate
of reaction in each well was measured as the slope of the steepest
increase in absorbance, namely the interval 0e205 s. Based on
these rates, a well concentration of 510 mM sodium L-lactate was
chosen for further optimization experiments.
For the second kinetics experiment [L-lactate] was held constant
and [APAD] was varied. A 21.3-mM solution of APAD in TB was
prepared (70.4mg in 5ml) and serially diluted by a factor of 2. Next,
62.5 ml of each APAD dilution, 62.5 ml of 510 mM sodium L-lactate in
TB, and 50 ml of 7 nM rcPfLDH in TBwere placed inwells in triplicate
of a UV-transparent 96-well plate such that the ﬁnal well concen-
trations were 510 mM APAD; 2 nM rcPfLDH; and 0.00, 0.119, 0.237,
0.474, 0.949, 1.9, 3.8, and 7.6 mM APAD. The plate was immediately
placed in a microplate reader, and absorbance was measured
(362 nm) in intervals of 25 s for 30 min. The rate of reaction in each
well was measured as the slope of the steepest increase in absor-
bance, namely the interval 0e205 s.
Finally, the signal-to-noise ratio of the PfLDH activity assay was
maximized. First, 25 ml of blank (0 nM) and positive control (14 nM)
rcPfLDH in TB were placed in separate wells of a 96-well plate. Next,
25 ml of NBT/PES solution (see “PfLDH activity assay reagents”
section below), 25 ml of 3.57 M lactate, and 100 ml of 0.58, 1.16, or
3.32 mM APAD were added to each well. The plate was covered
with foil and incubated for 30 min on an orbital plate shaker before
measuring absorbance (650 nm) on a plate reader. The assay was
performed in triplicate.
PfLDH activity assay reagents
The PfLDH activity assay required two solutions. First, sodium L-
lactate (4.00 g), tris(hydroxymethy)aminomethane (Tris, 1.32 g),
and APAD (0.022 g) were dissolved in 40ml of deionized (DI) water,
the pH was adjusted to 9.0, and the solution was diluted to 50 ml.
This Malstat solution was stored at 4 C. Second, NBT (0.080 g) and
PES (0.004 g) were dissolved in 50 ml of DI water. The NBT/PES
solution was wrapped in foil and stored at 4 C.
On-bead PfLDH activity assay
Solutions (100 ml) of parasitized lysed whole blood or rcPfLDH-
spiked lysed whole blood (see online supplementary material for
blood sample preparation) were placed in a Fisherbrand ﬂat-
bottom PS 96-well plate (cat. no. 12565501). Next, 5 ml of a-PfLDH
magnetic beads (MyOne Streptavidin T1) were added to each well
and incubated on an orbital shaker for 15 min. Using a MagWell
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separated from the supernatant and washed three times with
1  Tris-buffered saline with 0.05% Tween 20 (TBST). On the ﬁnal
wash, the beads weremoved to newwells. Next, 25 ml of TBST, 25 ml
of NBT/PES solution, and 125 ml of the prepared Malstat solution
were added to each well containing beads. The ﬁnal concentrations
of the PfLDH substrates in each well were 510 mM lactate and
0.474 mM APAD. The plate was immediately covered with Paraﬁlm
and foil and was incubated on an orbital shaker for 30 min. PfLDH
activity was assessed bymeasuring absorbance (580 nm) on a plate
reader. All assays were performed in triplicate. The limit of detec-
tion (LOD) was calculated as the concentration at the minimum
detectable signal (3SDblank þ sblank). See Fig. 1 for a summary of the
assay workﬂow.Fig.2. (A) Absorbance spectra for lysed whole blood (solid line) and products of PfLDH
activity assay (dashed line). (B) Analytical sensitivity of PfLDH activity assay at 580 nm
(0.810 ± 0.004 A580/nM) is nearly twice the sensitivity at 650 nm (0.479 ± 0.002 A650/
nM).Results and discussion
PfLDH activity assay optimization
The Malstat assay for PfLDH activity was optimized through
kinetic analysis andminimization of background signal. For optimal
determination of enzyme concentration, substrate concentrations
should be saturated tomaximize the rate of reaction. Two-substrate
enzyme-catalyzed reactions, such as PfLDH oxidizing lactate to
pyruvate using APADþ, obey simple MichaeliseMenten kinetics
when one substrate is held constant and the other is varied [12]. As
such, initial kinetics experiments were conducted in which
[APADþ] was held constant (0.474 mM) and [lactate] was varied
(0e1.02 M) while rcPfLDH was held constant (2 nM). Production of
APADH was followed at 362 nm. The corresponding curve (see
Fig. S1-A in supplementary material) demonstrated that 0.51 M
lactate yielded a saturating reaction rate and was selected for
further optimization experiments.
Next [lactate] was held constant (0.51 M) and [APADþ] was
varied (0e7.6 mM) at a constant rcPfLDH concentration (2 nM). The
resulting MichaeliseMenten curve revealed that saturating condi-
tions began at 1.9 mM APADþ (Fig. S1-B). However, when several
APADþ concentrations were tested in the PfLDH activity assay, it
was found that saturating conditions resulted in high background
signal, and 0.474 mM APADþ yielded the highest signal-to-noise
ratio (Fig. S2-A). For this reason, 0.474 mM was selected as the
optimal concentration for the PfLDH activity assay.
We postulate that the increase in background signal in the
PfLDH activity assay with increasing [APADþ] could be due to a
small amount of APADH contaminant. To support this hypothesis, a
standard curve of APADþ in TB was placed in a UV-transparent 96-
well plate. As shown in Fig. S2-B, absorbance at 362 nm, a
maximum for APADH, increased with increasing [APADþ], indi-
cating that APADH could account for 1.8 ± 0.5% reagent
contamination.Fig.1. Summary of workﬂow for oDetection of PfLDH was further optimized when it was discov-
ered that, although previous literature [5,10] measures progress of
the Malstat reaction at 650 nm, the wavelength of maximum
absorbance for the products of the PfLDH activity assay reaction is
580 nm. Others likely follow the reaction at 650 nm because
oxyhemoglobin in lysed whole blood has a peak in absorbance near
580 nm, which would interfere with the Malstat signal when the
assay is performed in the lysed blood sample [13] (Fig. 2A).
Measuring reaction progress at 580 nm results in a nearly 2-fold
enhancement of analytical sensitivity of the Malstat assay
(Fig. 2B). By using antibody-functionalized magnetic particles to
isolate and purify PfLDH from a blood sample and then performing
the Malstat assay directly on the solid phase, our assay strategyn-bead PfLDH activity assay.
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and takes advantage of the 2-fold enhancement at 580 nm.On-bead PfLDH activity assay
Capitalizing on the optimized assay conditions and enhanced
analytical sensitivity at 580 nm, we developed a strategy for mag-
netic capture and puriﬁcation of PfLDH that eliminates lysed whole
blood from the assay detection step. Magnetic capture beads were
synthesized by coupling biotinylated anti-PfLDH antibody to
commercially available streptavidin-coated magnetic particles.
These beads were incubated in a 96-well plate with lysed whole
blood spiked with rcPfLDH or lysed parasite culture to capture
PfLDH, washed, and incubated with PfLDH activity assay reagents
protected from light at the optimized conditions for 30 min. The
resulting signal was measured at 580 nm.
A standard curve for this immunomagnetic PfLDH activity assay
was ﬁrst developed in lysed whole blood spiked with rcPfLDH
(Fig. S3). The LOD of the assay was 25.7 ± 1.1 pM rcPfLDH, on the
same order of magnitude as commercially available pLDH enzyme-
linked immunosorbent assay (ELISA) kits. However, the developed
immunomagnetic PfLDH activity assay is 3e5 h shorter than a
typical ELISA. Fig. 3 shows the results of the on-bead PfLDH assay
for a titration of parasitized whole blood. The LOD was found to be
21.1 ± 0.4 parasites/ml. This detection limit is 2 orders of magnitude
lower than literature LODs for theMalstat assay performed in blood
samples due to the removal of blood from the detection step as well
as the thoroughly optimized substrate conditions and detection
wavelength [14]. Furthermore, our detection limit is less than half
of that found by Piper and coworkers for their 96-well plate-based
immunocapture pLDH activity assay, and the time-to-result for our
immunomagnetic assay (45 min) is shorter than the 1e2 h as re-
ported by Piper and coworkers [10].
Although in principle the developed immunomagnetic assay for
PfLDH is similar to the 96-well plate immunocapture Malstat
strategy developed by Piper and coworkers [10], the activity assay
reported here affords several advantages. The optimized assay re-
agent concentrations and detection wavelength are responsible, in
part, for our improved LOD. The use of magnetic microparticles for
immunocapture and puriﬁcation also contributes to the improved
detection limit for this assay; compared with a typical 96-well
plate, the microparticles used in this assay offer 40% more surface
area for antibody functionalization and antigen binding (1.3 vs.
0.9 cm2). Another advantage of capture and detection PfLDH on
magnetic particles is the reduced time-to-result. Active mixing ofFig.3. Parasite culture titration for immunomagnetic PfLDH activity assay.the magnetic beads with the sample also allows for a faster PfLDH
association time from a blood sample of 15 min compared with
30e60 min reported by Piper and coworkers. The decreased time-
to-result and low detection limit of the developed PfLDH assay
make it an attractive pLDH detection strategy in clinics and hos-
pitals in malaria-endemic areas.
Future directions include generalizing the developed assay to
detect pLDH from all species of malaria by functionalizing magnetic
particles with a pan-speciﬁc capture antibody or a series of species-
speciﬁc antibodies. Furthermore, aptamers, short single-stranded
oligonucleotide sequences capable of sensitive and speciﬁc recog-
nition of target molecules, are promising molecular recognition
elements for diagnostic applications due to their thermal stability.
In fact, Dirkzwager and coworkers successfully used aptamers in a
plate-based assay as capture agents for PfLDH, which was then
detectedwith a similar colorimetric pLDH activity assay (LOD¼ 600
parasites/ml) [15]. Conjugating an aptamer to magnetic particles for
pLDH isolation and puriﬁcation and using the optimized activity
assay we developed here would lead to a highly sensitive and
thermally stable diagnostic strategy for malaria.
Conclusions
We have developed a magnetic bead-based colorimetric assay
for PfLDH in which the biomarker is extracted from parasitized
whole blood and puriﬁed based on antigen binding to antibody-
functionalized magnetic particles. PfLDH activity was measured
on-bead using an optimized colorimetric enzyme turnover reaction
(LOD ¼ 21.1 ± 0.4 parasites/ml). The low detection limits and high
analytical sensitivity of this assay can be attributed to our opti-
mized assay conditions as well as removal of blood from the
detection step that would otherwise interfere with colorimetric
detection at the maximum wavelength for the diformazan assay
products. The developed assay represents a simple, effective, and
efﬁcient diagnostic strategy for P. falciparum malaria that could be
used in clinics or hospitals instead of time-consuming ELISAs for
pLDH. Future directions include generalizing this method for the
detection of all species of malaria by functionalizing magnetic
particles with a pan-speciﬁc pLDH antibody or a series of species-
speciﬁc pLDH antibodies.
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